63.81
price down icon0.05%   -0.03
after-market After Hours: 63.81
loading
Halozyme Therapeutics Inc stock is traded at $63.81, with a volume of 1.64M. It is down -0.05% in the last 24 hours and up +7.88% over the past month.
See More
Previous Close:
$63.84
Open:
$63.39
24h Volume:
1.64M
Relative Volume:
1.27
Market Cap:
$7.97B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
21.13
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
-0.33%
1M Performance:
+7.88%
6M Performance:
+11.48%
1Y Performance:
+56.86%
1-Day Range:
Value
$62.60
$64.07
1-Week Range:
Value
$62.60
$65.03
52-Week Range:
Value
$37.73
$66.00

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name
Name
Halozyme Therapeutics Inc
Name
Phone
(858) 794-8889
Name
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Name
Employee
0
Name
Twitter
@halozymeinc
Name
Next Earnings Date
2025-02-18
Name
Latest SEC Filings
Name
HALO's Discussions on Twitter

Compare HALO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
HALO
Halozyme Therapeutics Inc
63.81 7.97B 947.36M 392.47M 392.71M 3.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-07-24 Downgrade Wells Fargo Overweight → Equal Weight
Sep-19-24 Downgrade JP Morgan Overweight → Neutral
Jun-07-24 Downgrade Piper Sandler Overweight → Neutral
Feb-29-24 Initiated TD Cowen Outperform
Jul-24-23 Downgrade Goldman Buy → Neutral
Jul-24-23 Initiated H.C. Wainwright Buy
May-10-23 Upgrade Piper Sandler Neutral → Overweight
Mar-27-23 Resumed Berenberg Buy
Mar-16-23 Downgrade SVB Securities Outperform → Market Perform
Dec-21-22 Resumed Morgan Stanley Overweight
Nov-28-22 Initiated Wells Fargo Overweight
Sep-09-22 Initiated Morgan Stanley Overweight
May-23-22 Initiated SVB Leerink Outperform
Jun-14-21 Initiated Evercore ISI Outperform
May-17-21 Initiated SVB Leerink Outperform
May-11-21 Downgrade Piper Sandler Overweight → Neutral
Jan-21-21 Reiterated The Benchmark Company Buy
Dec-17-20 Initiated Berenberg Buy
Sep-14-20 Resumed JP Morgan Overweight
Jul-01-20 Initiated The Benchmark Company Buy
Feb-05-20 Upgrade Piper Sandler Neutral → Overweight
Jan-09-20 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-08-20 Initiated Goldman Buy
Nov-05-19 Upgrade Barclays Underweight → Equal Weight
Oct-19-18 Resumed Piper Jaffray Neutral
May-11-18 Downgrade Barclays Equal Weight → Underweight
Jan-24-18 Initiated Goldman Neutral
Oct-16-17 Reiterated Piper Jaffray Overweight
Jan-06-17 Downgrade Citigroup Buy → Neutral
Nov-03-16 Initiated Deutsche Bank Buy
Dec-04-15 Initiated Wells Fargo Outperform
Nov-18-15 Initiated Citigroup Buy
Sep-22-15 Initiated Barclays Overweight
Jun-22-15 Reiterated JP Morgan Overweight
Mar-03-15 Reiterated UBS Buy
Feb-18-15 Reiterated MLV & Co Buy
Jan-08-15 Reiterated MLV & Co Buy
View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

pulisher
12:27 PM

Corebridge Financial Inc. Has $9.81 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

12:27 PM
pulisher
11:00 AM

Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method - Nasdaq

11:00 AM
pulisher
08:30 AM

Major Breakthrough: New Cancer Drug Delivery Method Gets EU Panel Support - Stock Titan

08:30 AM
pulisher
Mar 28, 2025

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters.com

Mar 27, 2025
pulisher
Mar 27, 2025

Halozyme Therapeutics (HALO) Stock Price, News & Analysis - MarketBeat

Mar 27, 2025
pulisher
Mar 24, 2025

Halozyme stock soars to all-time high of $65.54 By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Halozyme stock soars to all-time high of $65.54 - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance

Mar 24, 2025
pulisher
Mar 21, 2025

Halozyme Announces Retirement of Chief Technical Officer - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme announces CTO retirement, effective immediately - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme announces CTO retirement, effective immediately By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Drug developers show mixed performance in early 2025 - BioWorld MedTech

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme Joins the $1 Billion Club - Yahoo Finance

Mar 21, 2025
pulisher
Mar 14, 2025

Halozyme Therapeutics: Steady Growth In A Challenged Market (NASDAQ:HALO) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Zacks Research Issues Negative Outlook for HALO Earnings - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Mar 13, 2025
pulisher
Mar 12, 2025

Smartleaf Asset Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

HALO vs. AMGN: Which Stock Is the Better Value Option? - Yahoo Finance

Mar 11, 2025
pulisher
Mar 11, 2025

Charles Schwab Investment Management Inc. Buys 9,780 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Insider Sell: Jeffrey Henderson Sells 5,000 Shares of Halozyme T - GuruFocus.com

Mar 10, 2025
pulisher
Mar 10, 2025

New version of Merck's Keytruda faces possible patent battle, WSJ reports - MSN

Mar 10, 2025
pulisher
Mar 08, 2025

Halozyme Therapeutics (NASDAQ:HALO) Earns Buy Rating from HC Wainwright - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Merck set for patent battle with Halozyme over injectable Keytruda: WSJ - MSN

Mar 07, 2025
pulisher
Mar 07, 2025

Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Mar 07, 2025
pulisher
Mar 07, 2025

H.C. Wainwright maintains Halozyme stock Buy rating, $72 target By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 06, 2025

High Growth Tech Stocks To Watch In US March 2025 - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

JMP maintains Halozyme stock $78 target amid Merck challenge - Investing.com India

Mar 06, 2025
pulisher
Mar 05, 2025

Exclusive | New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle - The Wall Street Journal

Mar 05, 2025
pulisher
Mar 05, 2025

Patent clash looms over Merck & Co.'s subcutaneous Keytruda - FirstWord Pharma

Mar 05, 2025
pulisher
Mar 05, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance

Mar 05, 2025
pulisher
Mar 05, 2025

Merck, Halozyme in patent battle over new Keytruda (MRK:NYSE) - Seeking Alpha

Mar 05, 2025
pulisher
Mar 04, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Halozyme director Jeffrey Henderson sells shares worth $293,458 - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Halozyme Therapeutics Director Sells 5,000 Shares - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Director Henderson Jeffrey William sold $293,458 worth of shares (5,000 units at $58.69), decreasing direct ownership by 13% to 33,611 units (SEC Form 4) - Quantisnow

Mar 03, 2025
pulisher
Mar 01, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Trimmed by Principal Financial Group Inc. - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $98,901.16 in Stock - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Michael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Los Angeles Capital Management LLC Has $4.42 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Halozyme Therapeutics SVP sells $1.26 million in stock By Investing.com - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Insider Sell Alert: Michael Labarre Sells Shares of Halozyme The - GuruFocus.com

Feb 27, 2025
pulisher
Feb 27, 2025

Halozyme Therapeutics SVP sells shares totaling $1.26 million By Investing.com - Investing.com South Africa

Feb 27, 2025

Halozyme Therapeutics Inc Stock (HALO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):